The easiest way to detect lung cancer is right under our nose
A new sampling layer for cancer — starting at the airway.
Blood is great, but it isn't enough
Lung cancer begins in the airway. Yet most liquid biopsy approaches rely on blood — a diluted, systemic signal.
Sampling from the nasal cavity accesses airway-derived genetic material at the anatomical origin of disease, revealing signals that blood alone may not capture.
Nasal and blood together create a more complete molecular picture.
Unlock up to 50% more biomarkers
Combining nasal and blood testing expands detectable signal for a more comprehensive molecular profile.
Sampling closer to lung biology
Captures airway-derived biomarkers at the anatomical origin of lung cancer.
Faster turnaround time
Easier to collect than blood — enabling quicker sample acquisition and processing.
No phlebotomist required
Enables decentralized collection in clinic or research environments.
Blood unlocked liquid biopsy But lung cancer begins in the airway
Liquid biopsy transformed oncology by moving beyond tissue.
But blood was never designed for lung cancer.
Plasma reflects what reaches circulation.
Lung cancer originates in the airway.
OncoSwab samples where the disease begins — accessing airway-derived genetic material through a simple nasal swab.
This isn't about replacing tissue.
It isn't about ignoring blood.
It's about starting in the right place.
From nose to insight
in three steps
Currently available for Research Use Only. Designed to power the next generation of non-invasive cancer detection.
Collect
A simple nasal swab, taken in minutes.
Extract
Isolate airway-derived genetic material.
Decode
Detect ctDNA mutations and cancer-associated biomarkers.
A new layer of lung cancer biology
By sampling the airway directly, OncoSwab enables researchers to study lung cancer at its point of origin — not just after it enters circulation. This opens study designs and biomarker strategies that were previously inaccessible with blood alone.
Longitudinal disease tracking
Repeat sampling over time to observe molecular changes closer to tumor origin.
Multi-site scalability
Standardized nasal collection across institutions, without reliance on blood-draw infrastructure.
Airway-driven biomarker discovery
Explore ctDNA and mutation signals enriched in the respiratory epithelium.
Every breakthrough in cancer testing starts with where you sample
Tissue was the first breakthrough.
Blood was the second.
Each expanded what researchers could see.
OncoSwab introduces airway-derived sampling as the next dimension — designed specifically for lung cancer biology.
As research evolves, the question is no longer just how sensitive a test is. It's whether you're sampling from the right place.
Active clinical studies are underway
Developed with hospitals from the start, now in multi-site clinical studies across multiple hospital partners.
Access the airway
OncoSwab is now available as a Research Use Only nasal sampling platform for lung cancer biomarker studies.
Designed for teams moving beyond blood-first approaches, the platform provides standardized nasal collection and airway-derived molecular analysis for multi-site and longitudinal research.
Built by clinicians and molecular biologists
A founding team spanning molecular biotechnology, translational research, and lung cancer clinical expertise.
Andrea Stephany, MSc
CEO & Co-founder
Serial entrepreneur. Biochemist. Science communicator.
Javier Zulueta, MD
Clinician co-founder & Chief Medical Advisor
+25 years in lung cancer screening. Former Chief of Pulmonary at Mount Sinai Morningside, NYC.
Roberta Gatta, PhD
Director of Clinical Operations
PhD in Biotechnology. Liquid biopsy expert.
Frequently Asked Questions
Is this available clinically?
Not yet. OncoSwab is currently offered as Research Use Only (RUO) while clinical validation is underway.
What studies is this best for?
Longitudinal cohorts, biomarker discovery, trial sub-studies, and workflows complementing liquid biopsy and tissue.
What does RUO access include?
Collection kits, documentation, molecular analysis and support for integrating into research protocols.
Is this intended to replace blood testing?
OncoSwab introduces a new sampling dimension for lung cancer research. How it ultimately integrates into clinical practice will depend on ongoing validation and study results.
Bring nasal biomarker sampling into your next study
Request RUO access and collaborate with OncoSwab as we expand clinical validation.
Request RUO Access